Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Clinical trial NCT07476326 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07476326
- Sponsor
- Biocon Biologics UK PLC
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2027-08-16
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.